子宮癌治療和診斷市場 - 全球產業規模、佔有率、趨勢、機會和預測，按癌症類型、治療方法、診斷方法、地區和競爭細分，2020-2030 年預測

2024 年全球子宮癌治療和診斷市場價值為 231 億美元，預計在預測期內將出現令人印象深刻的成長，到 2030 年的複合年成長率為 5.75%。 子宮癌，也稱為子宮內膜癌，是一種起源於子宮內膜的癌症。子宮是女性生殖器官，受精卵在懷孕期間在此著床，胎兒在此發育生長。當子宮內膜內異常細胞不受控制地生長時，就會發生子宮癌。子宮癌常表現為陰道異常出血、骨盆腔疼痛、排尿或排便習慣改變等症狀。子宮癌的危險因子包括肥胖、荷爾蒙失衡、家族病史、林奇症候群等某些遺傳疾病。子宮癌的診斷通常涉及病史評估、身體檢查、影像學研究（如經陰道超音波、MRI 或 CT 掃描）和組織活體組織切片（通常透過子宮內膜活體組織切片或擴張和刮除術獲得）。癌症分期有助於確定其擴散的程度並指導治療決策。子宮癌的治療因階段、類型和個別患者因素而異，但通常包括手術（如子宮切除術）、放射療法、化學療法、標靶療法，以及在某些情況下的免疫療法。早期發現和及時治療可以為許多子宮癌患者帶來良好的治療效果。改良的診斷技術，包括 MRI 和 CT 掃描等影像方式以及分子和基因檢測，使得能夠更早、更準確地診斷子宮癌。持續的研究和開發努力推動了子宮癌治療的創新。這包括標靶療法、免疫療法和新型化療藥物的開發。人口老化，特別是已開發國家的人口老化，導致子宮癌發生率上升。老年人罹患此類癌症的風險更高。

主要市場促進因素

老年人口不斷增加

主要市場挑戰

合併症和多學科護理

主要市場趨勢

精準醫療

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：全球子宮癌治療與診斷市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依癌症類型（子宮內膜腺癌、腺鱗癌、乳頭狀漿液性癌、子宮肉瘤）
  • 依治療方法（手術、免疫療法、放射線治療、化學療法、其他）
  • 透過診斷（活體組織切片、骨盆超音波檢查、子宮腔鏡檢查、擴張和刮除術、CT 掃描）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第 6 章：亞太地區子宮癌治療與診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 澳洲
  • 日本
  • 韓國

第 7 章：歐洲子宮癌治療與診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 西班牙
  • 義大利
  • 英國

第 8 章：北美子宮癌治療與診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 墨西哥
  • 加拿大

第 9 章：南美洲子宮癌治療與診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲子宮癌治療和診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 13 章：全球子宮癌治療與診斷市場：SWOT 分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

• Ariad Pharmaceuticals, Inc.
• Abbott Laboratories Inc.
• Becton, Dickinson & Co.
• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Novartis AG
• Sanofi SA
• Siemens Healthineers AG.
• F. Hoffmann-La Roche AG

第 17 章：策略建議

第18章 關於出版商,免責事項

Global Uterine Cancer Therapeutics & Diagnostics Market was valued at USD 23.10 Billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.75% through 2030. Uterine cancer, also known as endometrial cancer, is a type of cancer that originates in the lining of the uterus, called the endometrium. The uterus is a female reproductive organ where a fertilized egg implants and a developing fetus grows during pregnancy. Uterine cancer occurs when there is uncontrolled growth of abnormal cells within the endometrial lining. Uterine cancer often presents with symptoms such as abnormal vaginal bleeding, pelvic pain, and changes in urinary or bowel habits. The risk factors for uterine cancer include obesity, hormone imbalances, a family history of the disease, and certain genetic conditions like Lynch syndrome. Diagnosis of uterine cancer typically involves a combination of medical history evaluation, physical examination, imaging studies (such as transvaginal ultrasound, MRI, or CT scans), and tissue biopsy (usually obtained through endometrial biopsy or dilation and curettage). Staging of the cancer helps determine the extent of its spread and guides treatment decisions. Treatment for uterine cancer varies depending on the stage, type, and individual patient factors but often includes surgery (such as hysterectomy), radiation therapy, chemotherapy, targeted therapy, and, in some cases, immunotherapy. Early detection and timely treatment can lead to favorable outcomes for many uterine cancer patients. Improved diagnostic techniques, including imaging modalities like MRI and CT scans, as well as molecular and genetic testing, enabled earlier and more accurate diagnosis of uterine cancer. Ongoing research and development efforts led to innovations in uterine cancer therapeutics. This included the development of targeted therapies, immunotherapies, and novel chemotherapeutic agents. The aging population, particularly in developed nations, contributed to a higher prevalence of uterine cancer. Older individuals are at higher risk for this type of cancer.

Key Market Drivers

Rising Geriatric Population

The rising geriatric population is a key driver fueling the growth of the global uterine cancer therapeutics & diagnostics market. The global population aged 65 and older is expected to more than double, increasing from 761 million in 2021 to 1.6 billion by 2050. The 80+ demographic is expanding at an even faster rate. This irreversible demographic shift is set to reshape industries, drive demand for age-specific healthcare solutions, and create new market opportunities across pharmaceuticals, medical diagnostics, elderly care services, and insurance sectors. As the global population ages, the prevalence of uterine cancer-particularly endometrial cancer-has increased, leading to a higher demand for advanced diagnostics, innovative treatments, and specialized healthcare services. Below is a detailed analysis of how the aging demographic is shaping this market. Uterine cancer is more common among postmenopausal women, with the majority of cases diagnosed in women aged 50 and above. Endometrial cancer (EC) ranks as the sixth most prevalent cancer among women globally, with its incidence surging significantly over the past two decades. In 2019 alone, 435,041 new cases were diagnosed, resulting in 91,641 fatalities worldwide. This sharp rise underscores the growing burden on healthcare systems, accelerating demand for advanced diagnostics, targeted therapies, and innovative treatment solutions in the oncology market. As global life expectancy increases, the number of elderly women at risk also grows, leading to a direct rise in demand for cancer diagnostics and therapeutics. With an aging population, healthcare providers are prioritizing early detection and preventive screening programs to manage uterine cancer effectively. Governments and healthcare organizations are actively investing in: Routine gynecological screenings for older women, Biomarker-based diagnostic tests to detect cancer in early stages, AI-driven imaging solutions (MRI, PET scans) for precise detection. This increasing emphasis on early diagnosis and regular screenings is driving the market for diagnostic devices, pathology services, and molecular testing kits.

Key Market Challenges

Comorbidities and Multidisciplinary Care

Many uterine cancer patients have comorbid conditions, such as diabetes, hypertension, heart disease, or obesity. Managing uterine cancer alongside these comorbidities can complicate treatment decisions. Healthcare providers must weigh the benefits of aggressive cancer treatment against the potential risks and interactions with existing health conditions and medications. Comorbidities can affect a patient's ability to tolerate cancer treatments, such as surgery, chemotherapy, or radiation therapy. For example, individuals with heart disease may be at increased risk during surgery or may not tolerate certain chemotherapy regimens. Patients with multiple health conditions often take multiple medications. The potential for drug interactions between cancer therapies and medications for comorbidities must be carefully managed to avoid adverse effects. Due to the complexity of managing uterine cancer in patients with comorbidities, a multidisciplinary approach involving oncologists, surgeons, cardiologists, endocrinologists, and other specialists is often necessary. Coordinating care and communication among these specialists can be challenging. Each patient's case is unique, requiring individualized treatment plans that consider both the cancer and comorbidities. This necessitates close collaboration among healthcare providers. Determining the optimal sequencing of cancer treatments and interventions for comorbidities is crucial. For example, deciding whether to address heart disease or uterine cancer first can impact treatment outcomes.

Key Market Trends

Precision Medicine

Advances in genetic testing allowed for the comprehensive profiling of uterine cancer tumors. This profiling identified specific genetic mutations and alterations that drive cancer growth. Oncologists could use this information to select targeted therapies that were more likely to be effective for individual patients. Researchers were identifying and validating specific biomarkers associated with uterine cancer. These biomarkers could be used for early detection, prognosis assessment, and treatment decision-making. Precision medicine guided treatment decisions based on the molecular characteristics of a patient's tumor. This approach minimized the use of one-size-fits-all treatments and aimed to improve treatment efficacy while reducing side effects. Immunotherapy drugs, which stimulate the patient's immune system to target cancer cells, were being explored as part of precision medicine approaches for uterine cancer. Some patients with specific molecular profiles responded well to immunotherapy. Precision medicine was driving the design of clinical trials that focused on specific genetic subtypes of uterine cancer. These trials aimed to test new therapies and treatment combinations tailored to the molecular profiles of patients. Precision medicine also played a role in assessing a patient's risk of developing uterine cancer based on their genetic and environmental factors. This could inform prevention and early detection strategies.

Regional Insights

The North America region was the largest market in the Global Uterine Cancer Therapeutics & Diagnostics Market in 2024. North America, particularly the United States, has one of the highest healthcare spending rates in the world. This substantial investment in healthcare infrastructure and research and development contributes to advancements in uterine cancer therapeutics and diagnostics. The region boasts advanced healthcare facilities, medical technology, and a well-developed healthcare system. This allows for early detection, accurate diagnosis, and state-of-the-art treatment options for uterine cancer patients. North America is home to numerous pharmaceutical and biotechnology companies that invest heavily in cancer research, including uterine cancer. These companies develop innovative therapeutics and diagnostic tools for the market. The United States hosts a large number of clinical trials for various cancer types, including uterine cancer. Clinical trials are critical for testing new treatments and diagnostic methods, attracting patients from around the world.

Key Market Players

• Ariad Pharmaceuticals, Inc.
• Abbott Laboratories Inc.
• Becton, Dickinson & Co.
• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Novartis AG
• Sanofi SA
• Siemens Healthineers AG.
• F. Hoffmann-La Roche AG

Report Scope:

In this report, the Global Uterine Cancer Therapeutics & Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Uterine Cancer Therapeutics & Diagnostics Market, By Cancer Type:

• Endometrial Adenocarcinoma
• Adenosquamous Carcinoma
• Papillary Serous Carcinoma
• Uterine Sarcoma

Uterine Cancer Therapeutics & Diagnostics Market, By Therapeutics:

• Surgery
• Immunotherapy
• Radiation Therapy
• Chemotherapy
• Others

Uterine Cancer Therapeutics & Diagnostics Market, By Diagnostics:

• Biopsy
• Pelvic Ultrasound
• Hysteroscopy
• Dilation and Curettage
• CT scan

Uterine Cancer Therapeutics & Diagnostics Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Uterine Cancer Therapeutics & Diagnostics Market.

Available Customizations:

Global Uterine Cancer Therapeutics & Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Type (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, Uterine Sarcoma)
  • 5.2.2. By Therapeutics (Surgery, Immunotherapy, Radiation Therapy, Chemotherapy, Others)
  • 5.2.3. By Diagnostics (Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage, CT scan)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Type
  • 6.2.2. By Therapeutics
  • 6.2.3. By Diagnostics
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Type
      • 6.3.1.2.2. By Therapeutics
      • 6.3.1.2.3. By Diagnostics
  • 6.3.2. India Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Type
      • 6.3.2.2.2. By Therapeutics
      • 6.3.2.2.3. By Diagnostics
  • 6.3.3. Australia Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Type
      • 6.3.3.2.2. By Therapeutics
      • 6.3.3.2.3. By Diagnostics
  • 6.3.4. Japan Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Cancer Type
      • 6.3.4.2.2. By Therapeutics
      • 6.3.4.2.3. By Diagnostics
  • 6.3.5. South Korea Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Cancer Type
      • 6.3.5.2.2. By Therapeutics
      • 6.3.5.2.3. By Diagnostics

7. Europe Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Type
  • 7.2.2. By Therapeutics
  • 7.2.3. By Diagnostics
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Type
      • 7.3.1.2.2. By Therapeutics
      • 7.3.1.2.3. By Diagnostics
  • 7.3.2. Germany Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Type
      • 7.3.2.2.2. By Therapeutics
      • 7.3.2.2.3. By Diagnostics
  • 7.3.3. Spain Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Type
      • 7.3.3.2.2. By Therapeutics
      • 7.3.3.2.3. By Diagnostics
  • 7.3.4. Italy Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Type
      • 7.3.4.2.2. By Therapeutics
      • 7.3.4.2.3. By Diagnostics
  • 7.3.5. United Kingdom Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Type
      • 7.3.5.2.2. By Therapeutics
      • 7.3.5.2.3. By Diagnostics

8. North America Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Type
  • 8.2.2. By Therapeutics
  • 8.2.3. By Diagnostics
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Type
      • 8.3.1.2.2. By Therapeutics
      • 8.3.1.2.3. By Diagnostics
  • 8.3.2. Mexico Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Type
      • 8.3.2.2.2. By Therapeutics
      • 8.3.2.2.3. By Diagnostics
  • 8.3.3. Canada Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Type
      • 8.3.3.2.2. By Therapeutics
      • 8.3.3.2.3. By Diagnostics

9. South America Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Type
  • 9.2.2. By Therapeutics
  • 9.2.3. By Diagnostics
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Type
      • 9.3.1.2.2. By Therapeutics
      • 9.3.1.2.3. By Diagnostics
  • 9.3.2. Argentina Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Type
      • 9.3.2.2.2. By Therapeutics
      • 9.3.2.2.3. By Diagnostics
  • 9.3.3. Colombia Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Type
      • 9.3.3.2.2. By Therapeutics
      • 9.3.3.2.3. By Diagnostics

10. Middle East and Africa Uterine Cancer Therapeutics & Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Type
  • 10.2.2. By Therapeutics
  • 10.2.3. By Diagnostics
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Type
      • 10.3.1.2.2. By Therapeutics
      • 10.3.1.2.3. By Diagnostics
  • 10.3.2. Saudi Arabia Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Type
      • 10.3.2.2.2. By Therapeutics
      • 10.3.2.2.3. By Diagnostics
  • 10.3.3. UAE Uterine Cancer Therapeutics & Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Type
      • 10.3.3.2.2. By Therapeutics
      • 10.3.3.2.3. By Diagnostics

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Uterine Cancer Therapeutics & Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Ariad Pharmaceuticals, Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Product & Service Offerings
  • 16.1.3. Recent Developments
  • 16.1.4. Financials (If Listed)
  • 16.1.5. Key Personnel
  • 16.1.6. SWOT Analysis
• 16.2. Abbott Laboratories Inc.
• 16.3. Becton, Dickinson & Co.
• 16.4. GlaxoSmithKline Plc
• 16.5. Merck & Co., Inc.
• 16.6. Novartis AG
• 16.7. Sanofi SA
• 16.8. Siemens Healthineers AG.
• 16.9. F. Hoffmann-La Roche AG

17. Strategic Recommendations

18. About Us & Disclaimer